# Hangzhou Hanx Biopharmaceuticals

Source: https://onco.cc/companies/hangzhou-hanx-biopharmaceuticals/  
OnCo record `hangzhou-hanx-biopharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hangzhou Hanx Biopharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of HX009 in glioma & glioblastoma, biliary tract cancer and melanoma.

## Summary

Hangzhou Hanx Biopharmaceuticals, based in Wuhan, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HX009 in glioma & glioblastoma, biliary tract cancer and melanoma. The largest, NCT06708663 (HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours), plans to enrol 124 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Hangzhou Hanx Biopharmaceuticals, Ltd.
- Tags: ctgov-sponsor
- HQ: Wuhan
- Type: biotech
- Website: https://www.hanxbio.com

## Sources

- Official website: https://www.hanxbio.com
- ClinicalTrials.gov: trials led by Hangzhou Hanx Biopharmaceuticals: https://clinicaltrials.gov/search?lead=Hangzhou%20Hanx%20Biopharmaceuticals%2C%20Ltd.

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- trials: [A Phase 2 Study of HX301 in Patients with High-grade Giloma](https://onco.cc/trials/nct06703255/), [HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours](https://onco.cc/trials/nct06708663/), [HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies](https://onco.cc/trials/nct06649708/)

---
JSON: https://onco.cc/api/v1/entities/hangzhou-hanx-biopharmaceuticals.json